Back

Changes in echocardiographic parameters in heart failure with reduced ejection fraction patients treated with sacubirtil-valsartan: real-world experience in a newly-established heart failure program

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Fahad Alsendi

John Hopkins Aramco Healthcare, Dhahran (Saudi Arabia)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Association between initiation of sacubitril/valsartan and improved left ventricular ejection fraction in the real world
30 June 2021
thumbnail
Congress Presentation
New echocardiographic parameters for left ventricular dysfunction in patients with essential hypertension.
3 April 2025
thumbnail
Congress Presentation
Outcomes of TAVI in patients with heart failure with reduced ejection fraction
20 May 2023
thumbnail
Congress Presentation
Multiparametric evaluation of the effects of dapagliflozin in patients with heart failure and reduced ejection fraction
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources